Granulocyte apoptosis and their removal by phagocytes, particularly macrophages, is essential for resolution of inflammation.^[@bib1],\ [@bib2]^ The neutrophil, which although short-lived in the circulation, is granted an extended life span by survival signals at inflammatory sites.^[@bib3]^ Apoptosis renders these potentially histotoxic cells functionally redundant^[@bib4]^ and ensures their recognition and clearance by macrophages.^[@bib2]^ If this process is uncontrolled, then non-resolving chronic inflammation results. Neutrophils that are over-activated or undergo necrosis release their toxic granule contents, causing unwanted tissue damage. By inducing neutrophil apoptosis together with efficient macrophage removal, it is possible to promote the resolution of inflammation.^[@bib5]^ Indeed, delivery of apoptotic cells protects mice from endotoxin-induced shock,^[@bib5]^ highlighting a potential therapeutic role for inducing early apoptosis. Further approaches with equal translational promise include the use of cyclin-dependent kinase (CDK) inhibitor drugs,^[@bib6]^ aspirin-triggered 15-epi-LXA^[@bib8]^ and TRAIL (via specific death receptor signalling).^[@bib7],\ [@bib8]^

To drive neutrophil apoptosis, it is important to understand the mechanisms responsible for neutrophil survival. A key neutrophil survival protein is Mcl-1 as demonstrated by studies using anti-sense Mcl-1 RNA to 'knockdown\' Mcl-1 and Mcl-1 myeloid-specific knockout mice.^[@bib9],[@bib10]^ Mcl-1 confers a pro-survival effect by an interaction with pro-apoptotic Bcl-2 homologues (Bid, Bax, Bak) that prevents their association with the outer mitochondrial membrane and its subsequent permeabilisation thereby avoiding progression down the intrinsic apoptotic pathway.^[@bib11]^ An important pro-apoptotic Bcl-2 homologue responsible for regulation of neutrophil apoptosis, especially in the context of inflammation and cytokine-mediated extended longevity, is Bim.^[@bib12]^ We have shown that although Mcl-1 is downregulated at the level of transcription by the CDK inhibitor R-roscovitine protein levels of Bim are maintained.^[@bib13]^ Mcl-1 is an unusually large Bcl-2 homologue because it contains PEST domains in its C-terminal tail that target it for degradation by the proteasome^[@bib11]^ Rapid up or downregulation of transcription, a short half-life and extensive regulation, make Mcl-1 an ideal 'survival switch\' for regulating neutrophil apoptosis. Not only survival signals (e.g., GM-CSF) but also pharmacological agents (e.g., dexamethasone^[@bib15]^ and sodium salicylate^[@bib16]^) can alter Mcl-1 half-life and neutrophil survival, but there is still a niche for agents capable of driving resolution of inflammation. Our work suggests that CDK inhibitor drugs could fill this niche. R-roscovitine inhibits the activity of the CDKs 2, 5, 7 and 9.^[@bib14],\ [@bib15]^ CDKs 2, 7 and 9 all have roles in the regulation of transcription by the holoenzyme RNApol II.^[@bib14],\ [@bib15]^ This effect is mediated by phosphorylation of the C-terminal domain (CTD) and is inhibited by R-roscovitine in other cell systems.^[@bib16]^ The transcriptional capabilities of neutrophils have been questioned; however, key studies have demonstrated that neutrophils are transcriptionally active and that this function has great importance in immune defence.^[@bib17],\ [@bib18]^

This manuscript establishes for the first time in primary human neutrophils that CDK inhibitor-mediated inhibition of CDKs 7 and 9 prevents RNApol II phosphorylation leading to specific effects on transcriptional capacity, promoting apoptosis.

Results
=======

CDK and protein synthesis inhibitors induce neutrophil apoptosis
----------------------------------------------------------------

[Figure 1](#fig1){ref-type="fig"} demonstrates the time-course of neutrophil viability following CDK inhibitor drug treatment (R-roscovitine, [Figures 1a and b](#fig1){ref-type="fig"}; DRB (5,6-dichloro-1-beta-𝒟-ribofuranosylbenzimidazole), [Figure 1b](#fig1){ref-type="fig"}). Effects of CDK inhibitor drugs were similar to that observed with the transcription inhibitor actinomycin-D ([Figure 1a](#fig1){ref-type="fig"}) and the translation inhibitor cycloheximide (data not shown).^[@bib24]^ R-roscovitine (as we have previously shown^[@bib7]^), DRB and actinomycin-D promote apoptosis as determined by cell morphology ([Figure 1c](#fig1){ref-type="fig"}) and flow cytometry ([Figure 1d](#fig1){ref-type="fig"}).

Key regulators of RNApol II-mediated transcription in neutrophils
-----------------------------------------------------------------

Using genechip technology, we identified *CDK* gene expression levels in untreated/unstimulated neutrophils compared with neutrophils stimulated with LPS (*Escherichia coli* O127:B8, a bacterial product that delays neutrophil apoptosis^[@bib3],\ [@bib25]^), R-roscovitine or LPS plus R-roscovitine ([Figure 2](#fig2){ref-type="fig"}). The most strongly expressed CDKs were *CDKs 7 and 9* ([Figure 2a](#fig2){ref-type="fig"}). Interestingly, LPS stimulated *CDKs 2 and 7* gene expression ([Figure 2a](#fig2){ref-type="fig"}) that was inhibited by \>50% by R-roscovitine. The cyclin-binding partners of CDK7 and 9 (cyclin H and cyclin T1, respectively) were expressed at higher levels than other cyclins (*cyclin D1* shown for comparison; [Figure 2b](#fig2){ref-type="fig"}). *Cyclin H* expression was negatively regulated by R-roscovitine. MAT1 (ménage a trois 1; part of the transcription factor complex IIH (TFIIH) that contains CDK7) was expressed at low levels and unaffected by treatment. Endogenous CDK inhibitors, *p21 variant (v)1* and *p27*, were expressed at the gene level and *p21v1* was upregulated by LPS treatment ([Figure 2c](#fig2){ref-type="fig"}). By comparison, *p21v2* was only minimally expressed.

Western blotting of neutrophil total lysates was performed to investigate expression of CDKs at the protein level. We initially concentrated on CDKs known to be inhibited by R-roscovitine. CDK5, 7 and 9 were highly expressed, whereas CDK2 appeared to be minimally expressed with only a faint band observed ([Figure 3a](#fig3){ref-type="fig"}). Low levels of CDK2 protein in human neutrophils were confirmed by comparing lysates with those prepared form the proliferating cell lines HL-60 and HepG2 ([Figure 3c](#fig3){ref-type="fig"}). Differential nuclear and cytoplasmic lysis was subsequently performed to investigate the sub-cellular distribution of CDK proteins ([Figure 3b](#fig3){ref-type="fig"}). Antibodies to GAPDH and histone H3 confirmed differential fractionation, with GAPDH being exclusively cytoplasmic and a histone H3 complex predominantly expressed in the nuclear fraction. The minimal CDK2 that was observed appeared to be preferentially located in the cytoplasmic fraction ([Figure 3b](#fig3){ref-type="fig"}). CDK5 was readily detected and was distributed between the cytoplasmic and nuclear fractions. There appeared to be an increase in the nuclear fraction of CDK5 on stimulation with LPS that was blocked by co-treatment with R-roscovitine. CDK7 was readily detected in both cytoplasmic and nuclear fractions. Both isoforms (55 and 43 kDa) of CDK9 were readily detected in the neutrophils and appeared equally distributed between nuclear and cytoplasmic fractions. There was no obvious effect of LPS stimulation or R-roscovitine treatment on the distribution or levels of either isoform of CDK9. The binding partner cyclins of CDKs 7 and 9 (cyclin H and cyclin T1, respectively) were predominantly expressed in the nuclear fraction and there was minimal impact of LPS stimulation or R-roscovitine treatment on this distribution ([Figure 3b](#fig3){ref-type="fig"}).

To further investigate the western blotting observations for CDK7 and 9, confocal microscopy was performed in both unstimulated and LPS-stimulated neutrophils ([Figures 3d--g](#fig3){ref-type="fig"}). CDKs 7 and 9 were identified within the nucleus and cytoplasm by confocal imaging in both conditions that confirmed our western blotting data.

The CDK inhibitor drug R-roscovitine modulates phosphorylation of RNApol II in neutrophils
------------------------------------------------------------------------------------------

Recently, it had become apparent that neutrophils indeed have a capacity for *de novo* transcription.^[@bib17],\ [@bib26],\ [@bib27]^ The aim of this experiment was to identify neutrophil transcriptional machinery and to seek evidence for the involvement of CDKs 7 and 9 in the regulation of transcription. Phosphorylation of the CTD of RNApol II, which consists of 52 repeats of heptapeptide Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (YSPYSPS), provides a functional assay for CDK7 and 9 activity. CDK7 phosphorylates RNApol II serine 5, whereas CDK9 phosphorylates predominantly serine 2 (though it can phosphorylate both under certain conditions in different cell types). In [Figure 4](#fig4){ref-type="fig"}, the total RNA polymerase protein complex and RNA polymerase phosphorylated on key serine residues at position 2 (PS2) and 5 (PS5) are identified by western blotting with densitometry quantification. Phosphorylation on these serine residues is of known importance to the regulation of transcription by CDKs 7 and 9. Significant time-dependent loss of phosphorylation at serine residues 2 and 5 when neutrophils were incubated with the CDK inhibitor R-roscovitine is shown ([Figures 4a--c](#fig4){ref-type="fig"}). There was no significant change in total RNApol II with R-roscovitine treatment ([Figure 4d](#fig4){ref-type="fig"}). In addition, the RNApol II protein was identified in untreated neutrophils by indirect immunofluorescence detected by confocal microscopy ([Figure 4e](#fig4){ref-type="fig"}). It appeared that RNApol II levels were enhanced following stimulation of neutrophils with LPS, consistent with enhancement of active gene transcription.

R-roscovitine affects global gene transcription in LPS-stimulated and -unstimulated primary human neutrophils
-------------------------------------------------------------------------------------------------------------

In [Figure 5](#fig5){ref-type="fig"}, global effects on gene expression for neutrophils treated with R-roscovitine are illustrated by representative bar graphs and a heat-map. The heat-map shows the genes most significantly up and downregulated across all the four treatment conditions (untreated neutrophils (C), R-roscovitine-treated (R), LPS-stimulated (L) and LPS/R-roscovitine co-treatment (RL)). In the total of genes detected, 1656 genes were downregulated, 886 were upregulated and 1359 were not significantly affected following treatment with R-roscovitine for 4 h. Genes related to transcription were highly represented in terms of differential regulation following R-roscovitine treatment. In [Figure 5](#fig5){ref-type="fig"}, the impact on transcription-related genes as well as data for further gene types of specific interest to this work (apoptosis, inflammation, cell-cycle) are clearly demonstrated. The general trend is of gene downregulation following R-roscovitine treatment. Using gene ontology cluster analysis ([Table 1](#tbl1){ref-type="table"}), it was possible to identify clusters of genes that are most affected by R-roscovitine treatment.

Differential effect of the CDK inhibitor drug R-roscovitine on regulators of neutrophil apoptosis
-------------------------------------------------------------------------------------------------

We hypothesised that if the mechanism of action of R-roscovitine-driven neutrophil apoptosis was related to an effect on transcription, it might be prevented or at least delayed by the stabilisation of Mcl-1. This might have been achieved by transfection/transduction approaches, but these techniques have yet to be consistently and reliably applied to primary human neutrophils.^[@bib28]^ Therefore co-treatment with a proteasome inhibitor was utilised. Mcl-1 is an unusual Bcl-2 homologue in that it has a PEST domain that targets it for degradation in the proteasome in under 2 h.^[@bib11]^ [Figure 6a](#fig6){ref-type="fig"} shows that R-roscovitine-mediated loss of neutrophil viability was reversed at 8 and 12 h with the proteasome inhibitor MG-132. MG-132 treatment, even in the presence of R-roscovitine, prevented loss of Mcl-1 protein levels ([Figure 6b](#fig6){ref-type="fig"}). This was in contrast to the use of the caspase inhibitor z-VAD-fmk that did not prevent R-roscovitine-induced Mcl-1 downregulation ([Figure 6b](#fig6){ref-type="fig"}). Prevention of neutrophil apoptosis with MG-132 was only evident if MG-132 was administered within 2 h of R-roscovitine treatment (data not shown), suggesting that Mcl-1 loss was an early and key event in the induction of apoptosis.

To support the hypothesis that Mcl-1 is essential to neutrophil survival and that its downregulation by R-roscovitine leads to apoptosis, it was important to show that pro-apoptotic bcl-2 homologues were not downregulated in a similar fashion. The pro-apoptotic bcl-2 homologue Bim is prominent in neutrophil apoptosis and is especially relevant to apoptosis of cytokine-stimulated neutrophils.^[@bib12]^ Other bcl-2 homologues of relevance to neutrophil apoptosis include Bax, Bid and Bad. We have shown that Bim protein is preserved throughout a 4-h treatment with R-roscovitine.^[@bib13]^ At the level of gene expression, *Bim* was significantly upregulated, whereas *Bax* was significantly downregulated and other pro-apoptotic Bcl-2 homologues remained unaffected ([Figure 6d](#fig6){ref-type="fig"}). Pro-survival Bcl-2 homologues were unaffected at gene expression level, apart from Mcl-1, which was significantly downregulated ([Figure 6c](#fig6){ref-type="fig"}).

To further assess the relevant apoptotic pathways, we investigated mitochondrial membrane integrity ([Figure 6e](#fig6){ref-type="fig"}). Mitocapture dye accumulates in mitochondria of viable cells and fluoresces orange/red, whereas in the apoptotic cells, it leeches out of permeabilised mitochondria into the cytoplasm where it fluoresces green. Using this dye, we demonstrated significant induction of mitochondrial permeabilisation by R-roscovitine at early time-points where there was no evidence of morphological changes of apoptosis. Western blotting for the pro-apoptotic protein Bid revealed no evidence of cleavage throughout the time-range where apoptosis occurred (data not shown). R-roscovitine activated the caspase cascade, with the evidence of caspase-9 and -3 cleavage (activation) by western blotting after 4 h incubation ([Figure 6f](#fig6){ref-type="fig"}).

The CDK inhibitors DRB and R-roscovitine drive resolution of inflammation in the bleomycin-induced lung injury model
--------------------------------------------------------------------------------------------------------------------

We investigated the ability of CDK inhibitor drugs to resolve neutrophilic inflammation associated with the bleomycin lung injury model ([Figure 7a](#fig7){ref-type="fig"}). Bleomycin-induced lung injury has been a gold standard model for investigation of lung inflammation and fibrosis with similar pathology to the human disease idiopathic pulmonary fibrosis. Mice subjected to bleomycin injury develop significant bronchoalveolar lavage (BAL) neutrophilia ([Figure 7b](#fig7){ref-type="fig"}) and a measurable increase in BAL protein ([Figure 7d](#fig7){ref-type="fig"}) on day 7 consistent with inflammatory injury. By contrast, mice subjected to bleomycin injury, but treated with DRB or R-roscovitine, have less neutrophils in BAL with no detrimental effect on macrophage numbers ([Figures 7b and c](#fig7){ref-type="fig"}). Additionally, there is significantly less protein in BAL of CDK inhibitor-treated mice compared with vehicle controls ([Figure 7d](#fig7){ref-type="fig"}). There is an apparent trend towards less cell damage as measured by lactate dehydrogenase release in BAL of CDK inhibitor-treated mice but this did not reach statistical significance ([Figure 7e](#fig7){ref-type="fig"}). Histological evidence of neutrophil-dominant inflammation was clear in control animals at day 7, but in R-roscovitine- or DRB-treated animals, the inflammation was markedly attenuated with reductions in inflammatory cell infiltration in the alveoli, peri-bronchiolar and peri-vascular areas ([Figure 7f](#fig7){ref-type="fig"}). This is in contrast to untreated mice where neutrophils persist and significant architectural disturbance occurs resulting in fibrosis. To increase the novelty of this experiment and to further assess the potential of CDK inhibitor drugs to translate to clinical therapeutics, it should be noted that we delivered the CDK inhibitors via the *i.t.* route to mimic the delivery of standard inhaled therapies. This allowed us to decrease the total dose delivered to 10 mg/kg (a 10-fold lower dose than used in our previous study^[@bib7]^).

Discussion
==========

Our discovery that CDK inhibitor drugs (specifically R-roscovitine and DRB) induce neutrophil apoptosis was unexpected given the cell cycle status of terminally differentiated neutrophils. The only other terminally differentiated cell type (neurons) studied with these pharmacological agents demonstrated enhanced longevity.^[@bib29]^ Moreover, Klausen *et al.*,^[@bib30]^ using primary healthy human bone-marrow cells, described progressive loss of CDKs 2, 4 and 6, which began at the myelocyte/metamyelocyte stage and was almost complete by full maturation. This coincided with upregulation of the endogenous CDK inhibitor p27kip1. No consistent finding with regard to the up or downregulation of the CDK-binding partners, termed cyclins, was obtainable illustrating the complexity of regulation involved in this system. This finding was important as other works on granulopoiesis had utilised a variety of cell lines and discovered several CDK/CDK-binding partner expression patterns. Interestingly, the endogenous CDK inhibitor p21 has been described as a novel modulator of the macrophage response to LPS.^[@bib31],\ [@bib32]^ We have demonstrated functional CDKs, their binding partners and endogenous inhibitors and transcriptional machinery (both at gene and protein level) and identified specific transcriptional effects of the CDK inhibitor drugs in neutrophils. Perhaps unsurprisingly, given the terminally differentiated state of these cells, the most significantly expressed CDKs^[@bib7],\ [@bib9]^ have no direct role in the cell cycle but are essential for transcription of a key subset of genes.^[@bib33],\ [@bib34]^ This correlates well with our finding of a similarity in the kinetics of apoptosis induced by CDK inhibitor drugs and the protein transcription inhibitor actinomycin-D and the protein translation inhibitor cycloheximide.

The standard model of transcription from a promoter involves the binding and formation of a pre-initiation complex composed of RNApol II and various TATA box-binding proteins, kinases and ubiquitin ligases. This RNApol II holoenzyme is responsible for the majority of RNA transcription in mammalian cells. The pre-initiation complex requires further input before full-length, viable mRNA is produced. In highly inducible genes such as those involved in inflammatory signalling or apoptosis, RNApol II recruitment and activation occur simultaneously. These genes are heavily dependent on the positive transcription elongation factor b (P-TEFb) complex. P-TEFb is a heterodimer of CDK9 and cyclin T1 that can phosphorylate serines 2 and 5. Interestingly, NF-*κ*B-dependent genes are reliant on P-TEFb activity and there may be a physical interaction between NF-*κ*B and P-TEFb.^[@bib35],\ [@bib36]^ CDK7, cyclin H and the cofactor MAT1 are part of the TFIIH that is important for the initiation of transcription. LPS stimulation enhances *CDK7* gene transcription, suggesting that enhanced transcription directly drives transcription machinery production ([Figure 2a](#fig2){ref-type="fig"}). This process is downregulated by R-roscovitine. It should be noted that other proteins have been shown to have an effect on the phosphorylation status of the CTD of RNApol II including CDK1, CDK2, CDK8 and ERK.^[@bib38]^ Of these, CDK1 and 8 negatively regulate phosphorylation so their inhibition would be expected to result in increased phosphorylation and CDK2 has an indirect regulatory effect on CDK7. We have previously investigated ERK in the context of CDK inhibition and found no effect on its activity.^[@bib14]^ In this manuscript, we show very minimal CDK2 expression at the protein level and almost none within the nucleus, so it would seem an unlikely target. Our work with the CDK7- and 9-specific inhibitor, DRB, also argues against a significant role for CDK2.

We hypothesised that it was inducible genes (short-lived, rapidly upregulated, responsive and dependent on CDK activation) that allow fine control of neutrophil apoptosis ([Figure 6](#fig6){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). To support this contention, we have demonstrated that RNApol II is both present in neutrophils and phosphorylated by CDKs 7 and 9 to enhance transcriptional capacity ([Figure 4](#fig4){ref-type="fig"}). Inhibition of CDKs 7 and 9 leads to dephosphorylation of this enzyme and downregulation of transcription. The transcriptional capacity of neutrophils has been a matter of some controversy. Work by Cassatella *et al.*^[@bib18]^ suggested that neutrophils do have the capacity for *de novo* transcription.^[@bib17],\ [@bib26]^ Here, we describe the machinery by which they achieve this functionality and a method by which it may be selectively altered to enhance apoptosis and resolution of inflammation.

Mcl-1 protein levels are rapidly downregulated by R-roscovitine before the induction of apoptosis ([Figure 6](#fig6){ref-type="fig"}). Inhibiton of the proteasome by MG-132 prevented both R-roscovitine-induced Mcl-1 downregulation and apoptosis. Although caspase inhibition by z-VAD-fmk prevented neutrophil apoptosis, this did not fully prevent Mcl-1 downregulation, suggesting Mcl-1 downregulation occurs upstream of caspase activation ([Figure 6](#fig6){ref-type="fig"}). It was important to examine the expression of other pro-apoptotic and anti-apoptotic bcl-2 homologues to present a comprehensive picture of apoptosis signalling within the CDK inhibitor-treated neutrophil. We have previously shown that Bim, a key pro-apoptotic bcl-2 homologue mediating neutrophil apoptosis, is maintained at the protein level despite R-roscovitine treatment.^[@bib13]^ The *Bim* knockout mouse phenotype had enhanced neutrophil survival^[@bib37]^ and two recent papers have shown Bim upregulation in neutrophils in models of inflammation *in vitro* and *in vivo*.^[@bib12],\ [@bib38]^ Our data are consistent with a relative excess of pro-apoptotic bcl-2 homologues occurring following downregulation of survival proteins (notably Mcl-1) by CDK inhibitor drugs, the net result being loss of mitochondrial membrane integrity and apoptosis. Mcl-1 is downregulated at the gene expression level by R-roscovitine and we hypothesise that this precedes and is responsible for the initiation of apoptosis as we measured changes in the level of this mRNA/protein at 2 h but detected only a small percentage of apoptosis by 4 h.

By demonstrating that Mcl-1 is downregulated at the level of gene expression, we corroborate our finding that direct inhibition of NF-*κ*B is not responsible for CDK inhibitor-driven neutrophil apoptosis.^[@bib13]^ We hypothesise that a more central, generalised effect on neutrophil transcription is responsible for the induction of apoptosis. This effect is particularly evident in granulocytes because of the importance of the short-lived protein Mcl-1 to their survival. The imbalance between Mcl-1 and Bim drives neutrophils towards the intrinsic apoptosis pathway. Neutrophils are extremely sensitive to the changes in the inflammatory and immune *milieu*, and their dependence on a highly regulated survival protein is an explanation for their rapid regulation of apoptosis. Our work adds to the literature, suggesting the fundamental importance of these proteins to neutrophil survival, and more importantly describes the fundamental mechanism of action of the CDK inhibitor drugs in the resolution of inflammation. Finally, we demonstrate the ability of a CDK7/9-specific pharmacological agent (DRB) to resolve lung inflammation in a well-characterised *in vivo* model.

The work herein provides an insight into the transcriptional machinery of the neutrophil and demonstrates that CDK inhibition is an appealing strategy for the manipulation of this machinery to drive neutrophil apoptosis. Importantly, we believe our findings will help to advance future trials of CDK inhibitor drug therapy in the promotion of resolution of inflammation.

Materials and Methods
=====================

Neutrophil isolation and assessment of apoptosis
------------------------------------------------

We isolated peripheral blood neutrophils from healthy, human volunteers (Lothian Research Ethics Committee approvals no. 08/S1103/38 or no. 1702/95/4/72) with the use of dextran sedimentation and Percoll gradients as described,^[@bib6],\ [@bib19]^ and cultured the cells (5 × 10^6^/ml, 37 ^o^C) in IMDM containing 10% autologous serum. The cells were incubated with reagents as indicated in the figures either in flat-bottomed 24-well plates or in 2 ml Eppendorf tubes in a humidified, 37 ^o^C incubator at 5% CO~2~ or on a shaking, temperature-controlled heat block. We assessed apoptosis by flow cytometry with a Coulter FACSCaliber flow cytometer (Beckman-Coulter, Brea, CA, USA), using annexin-V-conjugated FLUOS (Roche, Welwyn Garden City, UK) in combination with propidium iodide (PI) (Sigma-Aldrich, Dorset, UK) and used light microscopy of Diff Quick stained cytocentrifuged preparations to confirm the presence of morphological changes characteristic of apoptosis. R-roscovitine was obtained from Calbiochem. 5,6-Dichloro-1-*β*-𝒟-ribofuranosylbenzimidazole (DRB) and other chemicals were from Sigma-Aldrich unless stated otherwise.

Western blotting
----------------

Cells at a concentration of 5 × 10^6^/ml per condition were incubated at 37 ^o^C on a shaking heat block (for times and reagent concentrations see figure legends). Total cells lysates were prepared at 4 °C as previously described.^[@bib13],\ [@bib20]^ Neutrophils were pelleted by centrifugation at 3000 × *g* for 60 s and re-suspended either in whole-cell lysis buffer as described (Meijer and Raymond^[@bib14]^, standard lysis) or in 100 *μ*l of cytoplasmic lysis buffer (for nuclear/cytoplasmic differential lysis; AEBSF 0.5 mM, HEPES 50 mM, KCl 50 mM, MgCl~2~ 2 mM, EDTA 0.1 mM, aprotinin 10 *μ*g/ml, levamisole 2 mM, leupeptin 10 *μ*g/ml, sodium orthovanadate 1 mM, benzamidine 0.5 mM, *β*-glycerophosphate 10 mM, pepstatin A 10 *μ*g/ml, phenanthroline 1 mM, PMSF 1 mM). Sample was incubated on ice for 10 min then 10 *μ*l of NP-40 was added, briefly vortexed and centrifuged for 10 min at 4300 × *g*. Supernatant was removed (the cytoplasmic fraction), and the remaining cell pellet was re-suspended in 50 *μ*l of nuclear lysis buffer (as cytoplasmic plus NaCl 300 mM and glycerol 10%) and placed at 4 ^o^C plus constant shaking for 20 min to solubilise nuclear proteins. Samples were then centrifuged at 23 100 × *g* for 10 min and supernatant was removed (nuclear fraction). Protein concentration of lysates were assessed by BCA protein assay (Thermo Scientific, Cramlington, UK) to ensure equal protein loading and added to an appropriate volume sample buffer before boiling at 95 ^o^C for 2 min. Lysate were run on 10--12% precast gels (Thermo Fisher Scientific, Rockford, IL, USA) or on 4% polyacrylamide gels and transferred onto PVDF (Immobilon-P, Millipore, Herts, UK). Membranes were blocked for 1 h in 5% (wt/vol) dried milk/TBS/0.1% Tween-20 or 5% BSA TBS/0.1% Tween-20 (RNAPol II). Membranes incubated at 4 °C overnight with primary antibodies; Mcl-1 diluted 1 : 500 (mouse monoclonal from R&D, Abingdon, UK and rabbit polyclonal from Santa Cruz Biotechnology, Santa Cruz, CA, USA); *β*-actin diluted 1 : 10 000 (Sigma-Aldrich); CDK2, 5, 7 and 9 and cyclins T1 and H diluted 1 : 500 (Santa Cruz Biotechnology); RNAPol II diluted 1 : 250 (Covance, Princeton, NJ, USA); GAPDH diluted 1 : 20 000 (Sigma-Aldrich), Histone H3 diluted 1 : 5000 (Abcam, Cambridge, UK). Following 3 × 5 min washes in TBS/0.1%Tween-20, the blots were incubated with HRP-conjugated secondary antibody (Dako, Glostrup, Denmark) diluted 1 : 2500 for 1 h at room temperature before incubation with ECL reagents (GE Healthcare, Bucks, UK) exposure to BioMax MS-1 x-ray-sensitive film, and processing (X-Ograph Imaging Systems, Wilts, UK). Densitometry was carried out using ImageJ software (NIH, Bethesda, MD, USA). Where appropriate HL-60 and HepG2 cell lines were used as positive controls.

Immunofluorescence for neutrophil CDKs 7 and 9 and RNA pol II
-------------------------------------------------------------

Neutrophils at 2.5 × 10^6^/ ml were incubated with treatments in 2 ml Eppendorf tubes on a 37 ^o^C shaking heat block for the indicated time-points and pelleted by centrifugation at 300 × *g* for 4 min before resuspension and transfer to coverslips. They were then fixed for 20 min in 3% paraformaldehyde. After washing and quenching with 50 mM glycine, cells were re-suspended in 50 *μ*l of 10% goat serum (as secondary antibodies were goat) and blocked for 1 h. Supernatant was removed and coverslips were gently placed onto 100 *μ*l of indicated primary antibody diluted as indicated for 1 h. Following washing, the cells were incubated with 50 *μ*l of appropriate fluorescent-conjugated secondary antibody as well as nuclear stain (DAPI/PI, 2 *μ*l in 1 ml) for 1 h before further washing in PBS and finally ddH~2~O. All experiments included control slides incubated with no antibody, primary antibody alone or secondary antibody alone. Coverslips were transferred to slides and mounted with mowiol and nail varnish before visualisation on confocal microscope (Leica SP5, Leica Microsystems GmbH, Wetzlar, Germany).

Assessment of mitochondrial integrity
-------------------------------------

MitoCapture (Biovision, Milpitas, CA, USA) is a fluorescence-based tool for detecting changes in the mitochondrial transmembrane potential. Neutrophils were isolated as above and incubated with appropriate reagent at a concentration of 5 × 10^4^/ml in a flat-bottomed 96-well plate at 37 ^o^C, 5% CO~2~ for 2 h. MitoCapture kit used as per manufacturer\'s instructions. Fluorescence microscopy was performed using a Zeiss Axiovert S100 (Zeiss, Oberkochen, Germany) microscope. Cells fluorescing green had lost mitochondrial membrane potential, whereas those fluorescing orange/red had intact mitochondria. Three separate experiments with three replicates of individual treatments were performed. Photographs were made and 500 cells were counted per replicate.

RNA isolation
-------------

Neutrophil purity was confirmed by flow cytometry before RNA isolation was performed with an initial trizol (Life Technologies, Carlsbad, CA, USA) extraction stage followed by the use of a Nucleospin RNA II kit (Macherey-Nagel, Duren, Germany) as per manufacturer\'s instructions. RNA was quantified and assessed with the use of an Agilent Bioanalyser (Santa Clara, CA, USA) before the gene-chip assay was performed.

Illumina Gene Chip assessment of neutrophil transcriptome
---------------------------------------------------------

This was performed by ARK-genomics (Roslin, Midlothian, Scotland, UK) and subsequent bioinformatics data was generated by Dr. Jon Manning, CIR Bioinformatics division. Data output by the proprietary Illumina software were handled using modules of the R-based Bioconductor software suite (<http://www.bioconductor.org>). Version 1.14.0 of the 'lumi\' package formed the core of the analysis, providing the routines employed to read, adjust background intensity, transform and normalise the data. The 'variance stabilising transform\' suggested by this module\'s authors was employed in place of the more conventional log-transform, before robust spline normalisation. Annotation data were derived initially from an Illumina-provided annotation file, with complementary information taken from the chip-specific 'illuminaHumanv3\' and more generic 'lumiHumanAll\' Bioconductor annotation packages. The level and significance of differential expression for each probe was assessed by use of linear models and empirical Bayes from the 'Limma\' package and the resulting *P* values were adjusted for multiple testing by use of the Benjamini--Hochberg method. Fold changes were derived with the aid the 'gtools\' package. Processed data were stored in a relational database with a dynamic front-end for further analysis.^[@bib21],[@bib22],[@bib23]^

Administration of bleomycin sulphate and CDK inhibitor drugs
------------------------------------------------------------

Female C57BL/6J mice weighing a minimum of 20 g were used for all experiments. The mice were briefly anesthetised using Isofluorane and bleomycin sulphate (0.033 mg; Apollo Scientific, Cheshire, UK) administered to the lungs via the trachea (i.t.), in a volume of 50 *μ*l. On day 2 and 5 post-bleomycin administration, mice (6 per group) were treated i.t. with either 50 *μ*l of 0.05% DMSO vehicle control or 10 mg/kg of R-roscovitine or DRB.

BAL and histology
-----------------

Mice were killed 7 days after bleomycin or saline administration with a single 200 *μ*l intraperitoneal injection of sodium pentobarbitone (200 mg/ml). The lungs were cannulated via the trachea *in situ* using a fine cannula that was tied in place with a single suture and BAL was performed using three sequential washes of 0.8 ml ice-cold sterile 0.9% saline. All samples were centrifuged at 180 g for 5 min at 4 °C, the supernatants removed and the cell pellets resuspended in 0.5 ml sterile 0.9% saline. Total cell numbers were counted using a nucleocounter and cytocentrifuge smears prepared and stained with Diff Quick for differential cell-counts to be made. At least 300 cells per slide were counted and the results expressed as total number of neutrophils and macrophages in the lung lavage. Histological analysis of the 7 day experiments (3 mice per group) was undertaken without BAL to maintain tissue integrity and lung injury was assessed by histological examination of paraffin-embedded lung sections stained with hematoxylin and eosin.

Statistical analyses (excluding illumina data, see above)
---------------------------------------------------------

All experiments were performed at least three times unless stated otherwise and each treatment done in triplicate and the results are expressed as the mean±S.E.M. Data were analysed by an one-way ANOVA with a Student\'s Newman--Keuls multiple comparison *post hoc* test with a 95% confidence interval (InStat software, Graphpad Software Inc., La Jolla, CA, USA).
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![The CDK inhibitors R-roscovitine and DRB and the transcription inhibitor actinomycin-D drive human neutrophil apoptosis. (**a** and **b**) Time-course showing the change in neutrophil viability (defined as annexin-V-ve/PI-ve) over a 20-h time period in control, R-roscovitine (20 *μ*M), actinomycin-D (10 *μ*M) or DRB (20 *μ*M) -treated cells. (**c**) Representative cytocentrifuge preparations for examination of morphological changes associated with apoptosis (scale bar 5 *μ*m) and (**d**) representative flow cytometric analysis of annexin-V binding and PI staining plots at 8 h of culture. Data are representative of *n*=3 experiments of three separate replicates and are presented as mean±S.E.M.](cdd201280f1){#fig1}

![Analysis of CDKs, cyclins and endogenous CDK inhibitors in human neutrophils. Expression levels of human neutrophil CDKs (**a**), cyclins (**b**) and endogenous CDK inhibitors (**c**) as analysed by Illumina Gene Chip. Neutrophils isolated from four independent donors (*n*=4) and treated for 4 h with media alone (Control), R-roscovitine (20 *μ*M), LPS (100 ng/ml) or a combination before RNA isolation and interrogation by microarray. Result shows gene expression levels (fluorescence units, f.u.) as mean±S.E.M. Significant differences *P*\<0.001 between Control and R-roscovitine are shown as \*, between LPS and R-roscovitine/LPS as \#, and between LPS and control by +, analysed using ANOVA with *post hoc* multivariate analysis by Student\'s Newman--Keuls](cdd201280f2){#fig2}

![Human neutrophils express CDKs and their cyclin binding partners. (**a**) Whole cell or (**b**) cytoplasmic/nuclear differential lysates prepared after 4 h incubation in control, R-roscovitine (20 *μ*M), LPS (100 ng/ml) or R-roscovitine and LPS and blotted for CDKs known to be inhibited by R-roscovitine as well as the cyclin binding partners of CDKs 7 and 9. (**c**) Low levels of CDK2 in human neutrophils confirmed using the proliferating cell lines HL-60 and HepG2 as a positive control. Densitometry on *n*=3 presented as mean±S.E.M., analysed using ImageJ software. All gels are representative of at least *n*=3 experiments. Confocal microscopy in neutrophils either unstimulated (**d** and **e**) or stimulated with LPS (100 ng/ml) (**f** and **g**) and probed for CDK7 (**d** and **f**) or 9 (**e** and **g**) by indirect immunofluorescence. Panels show transmitted light/bright field (BF), DAPI nuclear staining (blue), and CDK7 or 9 staining (red), final panel shows merged image (MERGE) demonstrating nuclear co-localisation (pink). Size bar represents 5 *μ*m scale. Leica SP confocal microscope × 630 oil immersion. Representative images from at least *n*=3 experiments](cdd201280f3){#fig3}

![R-roscovitine inhibits RNApol II phosphorylation on serine 2 and serine 5. (**a**) Western blotting for RNApol II total (Pol tot), phosphorylated on serine 2 (PS2) and phosphorylated on serine 5 (PS5) after 2 and 4 h in control or R-roscovitine (20 *μ*M) treated neutrophils. Lysates were run on 4% acrylamide gels with blots shown representative of three experiments. Densitometry (*n*=3, mean±S.E.M.) for serine 2 (**b**) and serine 5 (**c**), normalised to total RNApol II levels (**d**). Statistical significance compared to relevant time-point control where *P*\<0.01 is shown as \*\* and *P*\<0.001 \*\*\* by ANOVA with *post hoc* multivariate analysis by Student\'s Newman--Keuls (with a 95% confidence interval). Confocal microscopy of RNApol II (total) in neutrophils either unstimulated (**e**) or stimulated with LPS (100 ng/ml) (**f**) by indirect immunofluorescence. Panels show transmitted light/bright field (BF), DAPI nuclear staining (blue), RNApol II (total) staining (red), final panel shows merged image (MERGE) demonstrating nuclear colocalisation (pink). Size bar represents 10 *μ*m scale. Leica SP confocal microscope × 630 oil immersion. Representative images are shown from *n*=3 experiments](cdd201280f4){#fig4}

![R-roscovitine effects on the neutrophil transcriptome. Neutrophils treated for 4 h with media alone or R-roscovitine (20 *μ*M) were subjected to RNA isolation before interrogation by Illumina Gene Chip microarray. (**a**) Bar graph shows number of genes down-regulated (\>2 fold) and up-regulated (\>2 fold) by R-roscovitine treatment compared to control. Specific gene families assessed include: (**c**) transcription, (**d**) apoptosis, (**e**) inflammation and (**f**) cell-cycle. (**b**) Heat map shows gene expression most changed (upregulated and downregulated) across the four treatment groups of R-roscovitine (R), R-roscovitine/LPS (RL), Control (C) and LPS alone (L). Neutrophils from 4 donors (n=4)](cdd201280f5){#fig5}

![R-roscovitine effects on apoptotic pathways. (**a**) Neutrophil viability assessed using flow cytometry for annexin-V/PI following culture with media alone (Control), R-roscovitine (20 *μ*M), MG-132 (50 *μ*M) or with a combination of R-roscovitine and MG-132. (**b**) Neutrophils at 5 × 10^6^/ml in IMDM containing 10% autologous serum were either lysed immediately (time 0) or incubated in either the absence (control) or presence of R-roscovitine (20 *μ*M), MG132 (50 *μ*M), zVAD-fmk (100 *μ*M) or combinations of these agents for 2 h, then lysed and immunoblotted for Mcl-1 or β-actin. Blots shown are representative of three experiments. (**c** and **d**) Effect of 4 h R-roscovitine (20 *μ*M) on gene expression of bcl-2 homologues (anti-apoptotic (**c**), pro-apoptotic (**d**)) measured by Illumina gene chip (*n*=4 donors). Result shows fold change in gene expression with statistical significance *P*\<0.001 shown by \*\*\*. (**e**) Mitochondrial membrane integrity analysed by mitocapture dye after 2 h incubation in medium alone (control), R-roscovitine (20 *μ*M) alone, MG-132 (50 *μ*M) or combined R-roscovitine and MG-132. Mitocapture fluoresces red/orange in the mitochondria of viable neutrophils (Mito intact, solid bars) and green in the cytoplasm of neutrophils with loss of mitochondrial outer membrane (transmembrane) potential (MOMP, striped bars; fluorescent microscopy × 320, scale bar 20 *μ*m). (**f**) Western blotting for cleaved (active) caspases 9 and 3 after incubation with media alone (**c**) or R-roscovitine 20 *μ*M (R) at the given time points. All experiments (*n*=3). Statistical significance compared to relevant time-point control *P*\<0.001 is shown as \*\*\* by ANOVA with *post hoc* multivariate analysis by Student\'s Newman--Keuls (with a 95% confidence interval)](cdd201280f6){#fig6}

![CDK inhibitors R-roscovitine and DRB resolve bleomycin-induced acute lung injury. (**a**) Schematic of experimental protocol. Analysis of BAL fluid at day 7 for (**b**) neutrophil numbers (**c**) macrophage numbers (**d**) total protein (**e**) lactate dehydrogenase. *n*=5, mean±S.E.M., statistically significant difference compared with vehicle control shown as \*\**P*\<0.01 or \*\*\**P*\<0.001 by ANOVA with a Student\'s Newman--Keuls multiple comparison *post hoc* test with a 95% confidence interval. (**f**) Representative histological images (stained with haematoxylin and eosin) at magnification × 100 (size bar 100 *μ*m scale)](cdd201280f7){#fig7}

###### Gene ontology analysis of neutrophil gene-clusters most affected by R-roscovitine treatment

       **Downregulated genes (\>twofold** ***P***\<**0.01)**      **Upregulated genes (\>twofold** ***P***\<**0.01)**
  ---- ---------------------------------------------------------- -----------------------------------------------------------
  1    Positive regulation of I-kappaB kinase/NF-*κ*B cascade     Translational elongation
  2    Response to unfolded protein                               Ribosomal small subunit biogenesis
  3    Protein transport                                          Immune response
  4    Regulation of programmed cell death                        rRNA processing
  5    Regulation of transcription from RNApol II promoter        Leukocyte activation during immune response
  6    Protein localisation                                       Lysosomal transport
  7    Cell cycle                                                 Negative regulation of interleukin-8 biosynthetic process
  8    mRNA processing                                            Positive regulation of pinocytosis
  9    Transcription initiation from RNA polymerase II promoter   Defence response to fungus
  10   Positive regulation of transcription                       Leukocyte activation

Illumina Gene Chip technology experiment on *n*=4 donors. Over-represented gene ontology terms in genes significantly up and downregulated (up and downregulation \>twofold, R-roscovitine compared to control with significance of *P*\<0.001)
